Linvoseltamab Carfilzomib RRMM Treatment Outcomes

Here’s a breakdown of the references provided, formatted for⁢ clarity:

1. Clinical Trial: https://clinicaltrials.gov/study/NCT05137054
2. Conference Abstract: Manier ⁤S, Ocio E, Martinez-Chamorro C, et al. Linvoseltamab (LINVO) + carfilzomib (CFZ) in patients (pts) with⁤ relapsed/refractory multiple myeloma ⁢(RRMM): Initial results ‍from the LINKERMM2 trial. 2025 International Myeloma Society ⁤Annual Meeting. September ⁤17, 2025, to September 20, 2025. Toronto, Canada.⁤ Abstract PA-064.
3. FDA Approval News: FDA grants accelerated approval to linvoseltamab-gcpt for relapsed or refractory multiple myeloma. FDA. July 2, 2025. Accessed September 19, 2025. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-linvoseltamab-gcpt-relapsed-or-refractory-multiple-myeloma